LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacteria from Medicinal Soil Kills Antibiotic-Resistant Pathogens

By LabMedica International staff writers
Posted on 07 Jan 2019
Print article
Image: Growth of the newly discovered Streptomyces sp. myrophorea, so named because it produces a distinctive fragrance similar to that of oil of wintergreen. Although superficially resembling fungi, Streptomyces are true bacteria and are the source of two-thirds of the various frontline antibiotics used in medicine (Photo courtesy of G. Quinn, Swansea University).
Image: Growth of the newly discovered Streptomyces sp. myrophorea, so named because it produces a distinctive fragrance similar to that of oil of wintergreen. Although superficially resembling fungi, Streptomyces are true bacteria and are the source of two-thirds of the various frontline antibiotics used in medicine (Photo courtesy of G. Quinn, Swansea University).
A novel strain of Streptomyces bacteria isolated from an Irish bog with soil having a long tradition of use in folk medicine was shown to possess potent anti-microbial properties especially against antibiotic resistant pathogens.

Traditionally a small amount of soil from the area of Boho, in the Fermanagh Scarplands (Northern Ireland) was wrapped in cotton cloth and used to heal many ailments including toothache, throat, and neck infections. An international team of microbiologists analyzed samples of this soil for the presence of Streptomyces, a well-known producer of antibiotics.

The investigators reported in the October 16, 2018, online edition of the journal Frontiers in Microbiology that they had isolated a novel (closest relative 57% of genome relatedness) Streptomyces sp. capable of growth at high alkaline pH (10.5) and tolerant of gamma radiation to four kGy (kilogray). Genomic sequencing identified many alkaline tolerance multi-resistance genes compared to S. coelicolor. For this reason, the investigators called the strain Streptomyces sp. myrophorea, isolate McG1, from the Greek, myro (fragrance) and phorea (porter/carrier).

In vitro tests demonstrated the ability of the Streptomyces sp. myrophorea, isolate McG1 to inhibit the growth of many strains of ESKAPE (an acronym encompassing the names of six bacterial pathogens commonly associated with antimicrobial resistance) pathogens; most notably carbapenem-resistant Acinetobacter baumannii (a critical pathogen on the WHO priority list of antibiotic-resistant bacteria), vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus (both listed as high priority pathogens). Follow-up in vitro tests showed that the isolate itself was resistant to 28 out of 36 clinical antibiotics.

Computer-based prediction of the isolate's antimicrobial potential by anti-SMASH (which allows the rapid genome-wide identification, annotation and analysis of secondary metabolite biosynthesis gene clusters) and RAST (which is a fully-automated service for annotating complete or nearly complete bacterial and archaeal genomes) software identified many secondary metabolite and toxicity resistance gene clusters (45 and 27, respectively) as well as many antibiotic resistance genes potentially related to antibiotic production.

Senior author Dr. Gerry Quinn, formerly at Swansea University (United Kingdom) and now a researcher at Ruđer Bošković Institute (Zagreb, Croatia), said, "The discovery of antimicrobial substances from Streptomyces sp.myrophorea will help in our search for new drugs to treat multi-resistant bacteria, the cause of many dangerous and lethal infections.

Related Links:
Swansea University
Ruđer Bošković Institute

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.